CRISPR in Europe: the patent landscape for 2018

The Broad Institute of MIT and Harvard may lose a substantial number of European patent claims covering CRISPR/Cas9, but it has at least one trump card to play before we get to that stage, one European patent attorney has told LSIPR.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Africa

Clearing a way through the CRISPR patent jungle

8 May 2018 There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested.

Europe

Broad Institute to appeal CRISPR patent revocation

17 January 2018 The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office to revoke one of its patents covering CRISPR/Cas9 technology.

Europe

CRISPR opposition hearing kicks off at EPO

16 January 2018 Today could play a pivotal role in the CRISPR patent landscape in Europe.